AI system Synthegy enables chemists to design molecules with natural language

Researchers at EPFL have developed Synthegy, an AI framework that lets chemists guide complex molecule synthesis using simple language instructions. The system combines traditional algorithms with large language models to evaluate and rank reaction pathways. It also aids in understanding reaction mechanisms, potentially speeding up drug discovery.

Creating complex molecules for drugs or materials traditionally demands years of expertise in retrosynthesis, where chemists work backward from a target compound to identify starting materials and reaction routes. Synthegy, developed by a team led by Philippe Schwaller at EPFL, changes this by allowing chemists to input natural language instructions, such as forming a ring early or avoiding protecting groups. Standard software generates pathways, which the AI then scores and explains for alignment with those goals, as described in a paper published in Matter. Andres M. Bran, the first author, said, 'With Synthegy, we're giving chemists the power to just talk, allowing them to iterate much faster and navigate more complex synthetic ideas.' The framework applies similar reasoning to reaction mechanisms, breaking them into electron movements and evaluating feasibility under specified conditions. In a double-blind study with 36 chemists providing 368 evaluations, the system's assessments matched human judgments 71.2% of the time. Larger language models excelled in analyzing functional groups and full routes. Bran added, 'The connection between synthesis planning and mechanisms is very exciting: we usually use mechanisms to discover new reactions that enable us to synthesize new molecules.' Contributors include the National Centre of Competence in Research Catalysis and b12 Labs. The journal reference is Andres M. Bran et al., Matter, 2026; DOI: 10.1016/j.matt.2026.102812.

Verwandte Artikel

Illustration of US Treasury Secretary warning bank executives about AI cyberattack risks from Anthropic's Claude Mythos.
Bild generiert von KI

US Treasury warns banks of AI cyberattack risks following Anthropic's Claude Mythos announcement

Von KI berichtet Bild generiert von KI

In the wake of Anthropic's unveiling of its powerful Claude Mythos AI—capable of detecting and exploiting software vulnerabilities—the US Treasury Secretary has convened top bank executives to highlight escalating AI-driven cyber threats. The move underscores growing concerns as the AI is restricted to a tech coalition via Project Glasswing.

A Chinese research team has developed an AI platform called GalaxyVS that screens potential drugs in seconds.

Von KI berichtet

Isomorphic Labs, a spinoff of Google DeepMind, announced that its AI-designed drugs are progressing to human trials. President Max Jaderberg shared the news at WIRED Health in London, highlighting a “broad and exciting pipeline of new medicines.” The development builds on DeepMind’s AlphaFold platform.

The UK government’s AI Security Institute has released an evaluation of Anthropic's Mythos Preview AI model, confirming its strong performance in multistep cyber infiltration challenges. Mythos became the first model to fully complete a demanding 32-step network attack simulation known as 'The Last Ones.' The institute cautions that real-world defenses may limit such automated threats.

Von KI berichtet

A repurposed breast cancer drug called MDL-001 has shown promise in lab and animal studies against a range of viruses, including flu, covid-19, RSV and norovirus. Developed by California-based Model Medicines using AI, the pill targets a conserved enzyme domain in viruses. A clinical trial is planned for early next year.

Diese Website verwendet Cookies

Wir verwenden Cookies für Analysen, um unsere Website zu verbessern. Lesen Sie unsere Datenschutzrichtlinie für weitere Informationen.
Ablehnen